MLTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
61.7M
-11.9%
70.0M
+7.4%
65.2M
-8.7%
71.4M
+17.7%
60.7M
R&D
50.2M
-7.9%
54.5M
-2.7%
56.0M
-7.6%
60.6M
+21.9%
49.8M
SG&A
11.4M
-26.2%
15.5M
+68.4%
9.2M
-14.7%
10.8M
-1.3%
10.9M
Operating Income
-61660000
+11.9%
-70024000
-7.4%
-65218000
+8.7%
-71434000
-17.7%
-60698000
EBITDA
-60764000
+12.2%
-69179000
-7.3%
-64467000
+8.8%
-70689000
-17.9%
-59956000
Net Income
-61805000
+11.3%
-69707000
-10.6%
-63018000
+10.9%
-70694000
-26.1%
-56051000
EPS (Basic)
$-0.84
+14.3%
$-0.98
-11.4%
$-0.88
+20.0%
$-1.10
-26.4%
$-0.87
EPS (Diluted)
$-0.84
+14.3%
$-0.98
-11.4%
$-0.88
+20.0%
$-1.10
-26.4%
$-0.87
Shares (Diluted)
73.9M
+3.7%
71.3M
+4.9%
68.0M
+7.3%
63.4M
+0.1%
63.3M
MoonLake Immunotherapeutics (MLTX) โ€” Financials